Profound Medical Standardizes on AcuityMD Intelligence Platform for MedTech as Foundation for Growing Organization
Nearly 60% of men diagnosed with low-risk prostate cancer are managed with active surveillance – a 'wait-and-see' approach – because traditional treatments often cause severe, permanent side effects such as incontinence and erectile dysfunction. Profound Medical provides patients with a better alternative for whole or partial gland ablation, whether for low-risk, intermediate-risk, or more severe disease states. Indicated for transurethral ultrasound ablation (TULSA) of prostate tissue, TULSA-PRO is the first incision-free, radiation-free treatment for prostate disease. The procedure, which is now reimbursed by Medicare with a Category 1 CPT code, can also be conveniently performed in various outpatient settings – hospitals, ambulatory surgery centers, and office-based laboratories (OBLs).
AcuityMD provided Profound Medical a smart, efficient way to accelerate the delivery of TULSA-PRO to healthcare providers.
Profound Medical had been using a general customer relationship management (CRM) system with spotty market data. As a fast-growing company, they needed a powerhouse system with integrated MedTech workflows that not only helped sales identify the providers that could benefit from TULSA-PRO but also incorporated reliable commercial intelligence to guide strategic decision-making. Profound Medical also wanted industry-specific functionality for territory, contract, and long-term customer engagement management. After reviewing AcuityMD's platform – including all modules Pipeline, Targeting, Markets, Territories, plus newer modules Contracts and Care Journeys, both launched in 2024 – and speaking to customer referrals, Profound Medical doubled-down on AcuityMD's entire suite.
'We are building something important and want to do it right alongside a technology provider that will partner with us as we grow,' said Tom Tamberrino, Chief Commercial Officer at Profound Medical. 'The people at AcuityMD are as driven to get TULSA-PRO into the market as we are, and their platform is proving instrumental to helping us identify which physicians are treating prostate disease and where, as well as uncovering the high-volume regions where we need to strategically hire more sales professionals.'
Tamberrino added, 'We wanted a solution that was more than a one-note sales tool or generic CRM. AcuityMD provides value not just for our sales professionals but also our regional leaders, financial team, marketers, and even manufacturing groups. It's a comprehensive platform solution that delivers industry intelligence that all our teams can use for better decision-making.'
AcuityMD's platform is built for the MedTech industry's unique commercialization process and combines streamlined workflows with robust data, enabling sales, marketing, and national accounts teams to build comprehensive strategies focused on their best opportunities.
'Profound Medical is solving a longstanding men's health problem by offering an innovative procedure for prostate disease that also preserves quality-of-life,' said Michael Monovoukas, CEO and co-founder of AcuityMD. 'We are proud to partner with Profound Medical to help identify their best opportunities so they can achieve their goals and bring revolutionary TULSA-PRO technology to as many patients as possible.'
AcuityMD is the intelligence platform for MedTech. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster to accelerate the adoption of medical technology.
SOURCE: AcuityMD
Copyright Business Wire 2025.
PUB: 02/26/2025 07:05 AM/DISC: 02/26/2025 07:06 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
22 minutes ago
- Business Insider
Russia is experimenting in Ukraine's robot war with uncrewed rocket launchers, hoverboards, and a box on wheels
Ukraine's drone industry has developed a wide array of new uncrewed ground vehicles, but Russian forces are innovating with their own designs, too. While Moscow has been testing remote ground-based weapons since the early years of the war, a wider variety of rudimentary — and sometimes unusual — designs have been emerging this summer. Take, for example, a remote-controlled four-wheel buggy that pro-Russian Telegram channels called an "assault" Termit drone from a battalion of the 58th Guards Combined Arms Army. Instead of a weapons system, it's fitted with a chair that can accommodate a single soldier. Its rear can stow weapons, food, and water containers, the popular Russian Telegram channel Military Informant wrote in a post on Wednesday. Notably, this Termit drone variant leaves the soldier completely exposed. Another unique type of Russian logistics ground drone was recently filmed by a Ukrainian first-person-view drone. A clip published on Sunday by Ukrainian drone crowdfunding activist Serhii Sternenko shows that the Russian design essentially featured an open box on wheels. Sternenko wrote that the ground drone was destroyed and was transporting provisions near the front lines. On Thursday, a Russian page dedicated to armor and artillery systems published schematics of a tracked, uncrewed multiple-launch rocket system that can fire 10 munitions at once. The page, wrote that the ground drone was being developed by a Moscow-based engineering firm. The drone appears to resemble the TOS-1A, a Soviet multiple-launch rocket system mounted on a tank chassis and operated by a three-person crew. However, the TOS-1A features 30 barrels, triple that of the new drone. Russian forces have also been experimenting with carrying explosives via remote-controlled hoverboards. One popular Russian military blogger, Two Majors, published several clips in April of a ground drone built with two hoverboard scooters. "They can be used as kamikaze vehicles, as vehicles with a smoke screen, as self-propelled observation vehicles, and even for demining," the Telegram channel wrote, asking followers to donate such scooters to the Russian military. Another Russian Telegram channel, Victory Drones, published images in May of similar ground drones fitted with TM-62 anti-tank mines. "The main advantages of such drones are stability provided by gyroscopes and low cost, which makes it possible to use them on a mass scale," it wrote. Then there's the "Dronobus." On August 8, the Russian state news agency TASS published photos of a ground-based uncrewed vehicle that acts as a roving mothership for fiber optic attack drones. TASS wrote that Russian defense engineers are developing the Dronobus, which it reported can accommodate two fiber optic drones with 15-km cables. Russian forces have been making new ground-based drones for years, such as a tracked platform with the Kornet anti-tank missile system that one unit said it tested in March 2023. But the appearance of more varied designs comes as Moscow and Kyiv vie for any possible advantage with uncrewed ground vehicles. In April, Russia's defense minister Andrey Belousov said Russian firms and volunteer organizations had developed "several hundred ground robotic systems." "This year we plan to deliver an order of magnitude more," Belousov said. Meanwhile, Ukraine has been marshaling resources to develop its own new ground-based combat drones, using them to fire at enemy positions, evacuate the wounded, gather intelligence, or drop explosives. Dubbed "iron soldiers" by Ukrainian officials, the use of such combat systems grows more critical as prolonged war strains Ukraine's supply of fresh troops.
Yahoo
an hour ago
- Yahoo
TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock
Molina Healthcare, Inc. (NYSE:MOH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 28, Ryan Langston, an analyst from TD Cowen, reiterated a 'Buy' rating on the company's stock, and the associated price target was lowered to $203.00. The analyst noted that Molina Healthcare, Inc. (NYSE:MOH) continues to effectively manage the medical costs in the challenging environment, mainly in Medicaid, where it is witnessing pressures in behavioral, pharmacy, and inpatient/outpatient care. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. Molina Healthcare, Inc. (NYSE:MOH) continues to actively work with state partners in order to restore Medicaid rates to appropriate levels. It has considered increased cost trends in the Medicare and Marketplace bids for 2026. Despite challenges, Molina Healthcare, Inc. (NYSE:MOH)'s strategic efforts and adjustments in rate filings reflect growth potential, justifying the analyst's rating. For FY 2025, the Premium revenue is expected to be ~$42 billion, reflecting an increase of ~9% from FY 2024. Molina Healthcare, Inc. (NYSE:MOH) expects its FY 2025 GAAP earnings to be no less than $16.90 per diluted share. Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter. Here is what the fund said: 'Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care company. The company is the fourth largest player in managed Medicaid and has consistently delivered industry-leading margins historically. In our view, this is thanks to Molina Healthcare's exceptional management team and culture of operational excellence. Moreover, we think Molina Healthcare has a long runway for growth given its small scale relative to peers and untapped opportunities in their Medicare and Marketplace business segments. Recently, the Medicaid industry has come under substantial pressure due to a challenging redetermination cycle and additional headwinds from legislation under the current administration. This provided the opportunity to, in our view, purchase shares in a best-in-class managed care company at depressed valuation on trough earnings.' While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
